Examination the efficacy of Mirabegron on patient with overactive bladder after treatment with a1 blocker for benign prostatic hyperplasia
Not Applicable
- Conditions
- Overactive bladder
- Registration Number
- JPRN-UMIN000019735
- Lead Sponsor
- Department of Urology, Shiga University of medical Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- Male
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
suspect of malignancy contraindication of Mirabegron using other anticholinergic agent using A1 blocker within 4 weeks using Dutasteride redidual urine over 50mL urinary infection
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method OABSS after twelve weeks
- Secondary Outcome Measures
Name Time Method